Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer
- PMID: 24661086
- DOI: 10.1517/14712598.2014.900540
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer
Abstract
Introduction: Chimeric antigen (or antibody) receptors (CAR) are fusion proteins typically combining an antibody-derived targeting fragment with signaling domains capable of activating immune cells. Recent clinical trials have shown the tremendous potential of adoptive cell transfer (ACT) of autologous T cells engineered to express a CD19-specific CAR targeting B-cell malignancies. Building on this approach, ACT therapies employing allogeneic CAR-expressing cytotoxic cells are now being explored.
Areas covered: The basic principles of CAR-ACT are introduced. The potential benefits as well as problems of using allogeneic CAR-modified cells against tumor antigens are discussed. Various approaches to allogeneic CAR therapy are presented, including donor leukocyte infusion, CAR-redirected γδ T cells and natural killer cells, strategies to avoid graft-versus-host disease, modulation of lymphocyte migration, and exploitation of graft-versus-host reactivity.
Expert opinion: CAR-modified allogeneic cells have the potential to act as universal effector cells, which can be administered to any patient regardless of MHC type. Such universal effector cells could be used as an 'off-the-shelf' cell-mediated treatment for cancer.
Keywords: CD19; FTY720; T-cell receptor disruption; adoptive cell transfer; allogeneic; cancer; chimeric antigen receptors; egress; graft-versus-host disease; graft-versus-tumor; her2/neuregulin; host-versus-graft; t-body; tumor.
Similar articles
-
NK-92 cell, another ideal carrier for chimeric antigen receptor.Immunotherapy. 2017 Aug;9(9):753-765. doi: 10.2217/imt-2017-0022. Epub 2017 Aug 3. Immunotherapy. 2017. PMID: 28771105 Review.
-
Versatile strategy for controlling the specificity and activity of engineered T cells.Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. doi: 10.1073/pnas.1524193113. Epub 2016 Jan 12. Proc Natl Acad Sci U S A. 2016. PMID: 26759368 Free PMC article.
-
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):200-215. doi: 10.1016/j.bbcan.2018.01.005. Epub 2018 Jan 31. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29378229 Review.
-
At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.J Leukoc Biol. 2016 Dec;100(6):1255-1264. doi: 10.1189/jlb.5BT1215-556RR. Epub 2016 Oct 27. J Leukoc Biol. 2016. PMID: 27789538 Free PMC article. Review.
-
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review.
Cited by
-
Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.Blood Adv. 2018 Jul 24;2(14):1691-1695. doi: 10.1182/bloodadvances.2018017004. Blood Adv. 2018. PMID: 30026294 Free PMC article.
-
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.Front Immunol. 2017 Jun 9;8:654. doi: 10.3389/fimmu.2017.00654. eCollection 2017. Front Immunol. 2017. PMID: 28649246 Free PMC article. Review.
-
The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle?Biomedicines. 2022 Feb 8;10(2):400. doi: 10.3390/biomedicines10020400. Biomedicines. 2022. PMID: 35203609 Free PMC article. Review.
-
Towards neuroimmunotherapy for cancer: the neurotransmitters glutamate, dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains.J Neural Transm (Vienna). 2014 Aug;121(8):1007-27. doi: 10.1007/s00702-014-1242-y. Epub 2014 Jul 17. J Neural Transm (Vienna). 2014. PMID: 25030361
-
From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.Front Immunol. 2017 Nov 13;8:1576. doi: 10.3389/fimmu.2017.01576. eCollection 2017. Front Immunol. 2017. PMID: 29181011 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
